why choose us

First received: December 26, 2022

Clinical Trial: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: Phase 2 Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor Targeting Agents (ARTA)

Brief Summary: The goal of this clinical trial is to examine the safety and efficacy of ONC-392 in combination with lutetium Lu 177 vipivotide tetraxetan in metastatic castration resistant prostate cancer patient who have disease progressed on androgen receptor pathway inhibition.The main questions it aims to answer are (1) whether it is safe to combine ONC-392 with lutetium Lu 177 vipivotide tetraxetan, (2) whether the combination increases the radiographic progression free survival (rPFS).Participants will be randomized to two…

Read more